We recently documented the first evidence of loss of a metabolic gene, AMP-activated protein kinase (AMPK), in ALD but not AMN patient-derived cells [9]. In vivo and in vitro studies have shown that AMPK signaling and proinflammatory responses are mutually coupled via negative feedback [10–12]. The gene discussed is PRKAA1; the disease is adrenomyeloneuropathy.